SciELO - Scientific Electronic Library Online

 
vol.25 número2Prevalencia de enteroparasitosis en una comunidad altoandina de la Provincia de Víctor Fajardo, Ayacucho, Perú índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Bookmark


Revista de Gastroenterología del Perú

versión impresa ISSN 1022-5129

Resumen

CAMPOS NIZAMA, Juan. Grado de inmunidad humoral y factores asociados a la respuesta a la vacunación contra el virus de la Hepatitis B en el personal de salud del Hospital Nacional Case-Essalud, Arequipa (Setiembre 1995 - Marzo 2002). Rev. gastroenterol. Perú [online]. 2005, vol.25, n.2, pp. 141-149. ISSN 1022-5129.

The serum levels of antibodies against the Hepatitis B virus, in employees of the Case-Essalud National Hospital of Arequipa, who have been vaccinated, were determined in order to evaluate the immunoresponse that the vaccination produces in them and the factors that may be involved in the said response. In this way the protection level that is being achieved may be known. MATERIAL AND METHODS: The study was carried out on 165 health employees of the Case-Essalud National Hospital of Arequipa who were administered the recombinant vaccination against the Hepatitis B Virus (HBV), via intramuscular injection in the deltoid region, applying the rapid scheme 0,1,2 months. A 1ml (30ug of antigen) dose was administered. The serum concentrations of anti-HBs (in mUI/ml) were found in the third month of the third dose, by the enzyme immunoassay method, AXSYM System of Abbot Laboratories. In accordance with the facts established, seroprotection levels were defined to be serum concentrations of anti-HBsAg antibodies greater than 10mUI/ml.  RESULTS: The results evidenced that the vaccine applied to the employees being studied, produced seroprotection levels 10mUI/ml in 94.54% of the employees. Besides, a lesser seroprotection response (p0.01) was seen in male employees, in those older than 40 years of age, in those with high TGP levels and in tobacco consumers. Whereas, no significant relation (p0.05) was observed between the immunogenic response and the pathological history of the employees vaccinated.  CONCLUSIONS: It may be concluded that the recombinant vaccine against the Hepatitis B Virus (HBV) produces an adequate measure of protection in a significant percentage of employees in Peru and that the response is significantly lesser in male employees, in those older than 40 years of age, in those with high TGP levels and in tobacco consumers.

Palabras llave : Hepatitis B; Immunization.

        · resumen en Español     · texto en Español